The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer
Targeted therapies have allowed for an individualized treatment approach in non-small-cell lung cancer (NSCLC). The initial therapeutic decisions and success of targeted therapy depend on genetic identification of personal tumor profiles. Tissue biopsy is the gold standard for molecular analysis, bu...
Main Authors: | Jatta Saarenheimo, Natalja Eigeliene, Heidi Andersen, Marja Tiirola, Antti Jekunen |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-03-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.00129/full |
Similar Items
-
Gene-Guided Treatment Decision-Making in Non-Small Cell Lung Cancer – A Systematic Review
by: Jatta Saarenheimo, et al.
Published: (2021-10-01) -
Metastatic Rectal Carcinoma with Long-Term Remission due to Modern Multimodality Treatment
by: Natalja Eigeliene, et al.
Published: (2021-10-01) -
Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer
by: Veldore VH, et al.
Published: (2018-01-01) -
EGFR‐plasma mutations in prognosis for non‐small cell lung cancer treated with EGFR TKIs: A meta‐analysis
by: Thang Thanh Phan, et al.
Published: (2022-08-01) -
Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer
by: Martin Pesta, et al.
Published: (2022-07-01)